ArticleFrontiers in endocrinology2025
Risk factors for advance stage cardiovascular-renal-metabolic syndrome in patients with early-onset type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the incidence of advanced cardiovascular-kidney-metabolic (CKM) syndrome and its associated risk factors in patients with early-onset type 2 diabetes mellitus (T2DM). Methods: This cross-sectional study enrolled 1830 T2DM patients attending Shanghai Seventh People's Hospital (July 2019-May 2025). Participants were stratified into early-onset (diagnosis age <40 years; n=509) and non-early-onset (n=1321) cohorts. Advanced CKM was defined as stages 3-4 per American Heart Association (AHA) criteria. Comparative analysis, restricted cubic spline (RCS) modeling, binary logistic regression, and receiver operating characteristic (ROC) curves were employed to characterize advanced CKM distribution and determinants. Results: Advanced CKM incidence was significantly lower in the early-onset group (31.2%, 159/509) versus the non-early-onset group (60.6%, 801/1321) ( Conclusion: Early-onset T2DM patients exhibit a lower incidence of advanced CKM than non-early-onset individuals, though risk escalates substantially with prolonged diabetes duration. UACR, BUN, and diabetes duration are independent risk factors, while greater subcutaneous fat area and antihypertensive therapy confer protection. The derived prediction model may facilitate early clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.